Krystal Biotech (NASDAQ:KRYS) Shares Up 7.6% Following Analyst Upgrade

Krystal Biotech, Inc. (NASDAQ:KRYS)’s share price traded up 7.6% during mid-day trading on Wednesday after Stifel Nicolaus raised their price target on the stock from $204.00 to $220.00. Stifel Nicolaus currently has a buy rating on the stock. Krystal Biotech traded as high as $199.89 and last traded at $199.00. 187,483 shares were traded during mid-day trading, a decline of 47% from the average session volume of 351,750 shares. The stock had previously closed at $185.00.

Several other equities analysts have also issued reports on KRYS. HC Wainwright lifted their price target on shares of Krystal Biotech from $200.00 to $221.00 and gave the stock a “buy” rating in a report on Wednesday, August 28th. Chardan Capital increased their price target on Krystal Biotech from $153.00 to $208.00 and gave the company a “buy” rating in a research note on Monday, August 5th. Cantor Fitzgerald reissued an “overweight” rating on shares of Krystal Biotech in a report on Thursday, August 29th. Evercore ISI upped their price objective on shares of Krystal Biotech from $201.00 to $206.00 and gave the company an “outperform” rating in a report on Monday, August 12th. Finally, William Blair upgraded shares of Krystal Biotech to a “strong-buy” rating in a research note on Friday, August 30th. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $196.75.

Institutional Investors Weigh In On Krystal Biotech

Several hedge funds and other institutional investors have recently added to or reduced their stakes in KRYS. Jamison Private Wealth Management Inc. purchased a new stake in shares of Krystal Biotech in the second quarter worth about $28,000. GAMMA Investing LLC lifted its stake in shares of Krystal Biotech by 160.3% in the 2nd quarter. GAMMA Investing LLC now owns 151 shares of the company’s stock valued at $28,000 after purchasing an additional 93 shares during the period. Key Financial Inc purchased a new stake in Krystal Biotech during the second quarter worth $28,000. Blue Trust Inc. grew its position in Krystal Biotech by 2,328.6% during the second quarter. Blue Trust Inc. now owns 170 shares of the company’s stock valued at $30,000 after buying an additional 163 shares during the period. Finally, Quest Partners LLC purchased a new stake in shares of Krystal Biotech during the 2nd quarter worth about $71,000. 86.29% of the stock is owned by institutional investors and hedge funds.

Krystal Biotech Trading Down 1.6 %

The stock has a 50-day moving average price of $195.69 and a 200 day moving average price of $178.27. The stock has a market capitalization of $5.59 billion, a price-to-earnings ratio of 104.62 and a beta of 0.82.

Krystal Biotech (NASDAQ:KRYS) last announced its earnings results on Monday, August 5th. The company reported $0.53 earnings per share for the quarter, topping the consensus estimate of $0.50 by $0.03. Krystal Biotech had a return on equity of 1.99% and a net margin of 63.73%. The business had revenue of $70.28 million during the quarter, compared to the consensus estimate of $65.27 million. During the same period in the prior year, the company posted ($1.25) EPS. The business’s quarterly revenue was up 70283900.0% on a year-over-year basis. Equities research analysts anticipate that Krystal Biotech, Inc. will post 3.13 earnings per share for the current year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).